The European Medicines Agency (EMA) has recommended approval of mCombriax, a first-of-its-kind mRNA vaccine offering protection against both COVID-19 and influenza, for individuals aged 50 years and older. This positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) marks a significant step toward providing a combined defense against two prevalent respiratory viruses, potentially simplifying vaccination schedules and bolstering public health efforts across the European Union. The development comes after the U.S. Food and Drug Administration (FDA) declined to review the vaccine, according to reports.
The recommendation, issued on February 26, 2026, is based on data from a pivotal Phase 3 clinical trial. MCombriax is designed for active immunization, aiming to prevent influenza and COVID-19 caused by SARS-CoV-2. If approved by the European Commission, it would become Moderna’s fourth marketed product in Europe, representing a major advancement in respiratory virus vaccination, according to Moderna CEO Stéphane Bancel. “Combination vaccines have the potential to simplify vaccination and support improved health outcomes,” Bancel stated in a press release.
A Novel Approach to Respiratory Virus Protection
mCombriax utilizes mRNA technology, building upon the success of Moderna’s existing COVID-19 vaccine, mNEXSPIKE®, and its investigational seasonal influenza vaccine, mRNA-1010. MRNA-1010 has likewise been submitted for review in the United States, the European Union, Canada, and Australia. The combination vaccine represents a shift in strategy, aiming to provide broader protection with a single dose, potentially increasing vaccination rates and reducing the burden on healthcare systems during peak respiratory virus seasons.
The CHMP’s positive opinion is a crucial milestone, but final authorization rests with the European Commission. Following Commission approval, individual EU member states will implement their own national regulatory and access procedures, determining how and when mCombriax will be made available to the public. The timeline for these national approvals will vary.
Building on Existing mRNA Technology
Moderna’s success with mRNA vaccines during the COVID-19 pandemic paved the way for this innovative combination approach. The company leveraged its existing mRNA platform to develop both the COVID-19 and influenza components of mCombriax, streamlining the development process and potentially accelerating the timeline to market. The vaccine’s design allows for a simultaneous immune response to both viruses, offering potentially enhanced protection.
The development of a combined flu and COVID-19 vaccine addresses a key public health need. Both viruses pose significant risks, particularly to older adults and individuals with underlying health conditions. A single vaccine could simplify vaccination campaigns, improve compliance, and reduce the logistical challenges associated with administering multiple shots.
What the Approval Means for Public Health
The EMA’s recommendation is particularly noteworthy given the ongoing evolution of both influenza and SARS-CoV-2. New variants continue to emerge, necessitating frequent updates to existing vaccines. A combination vaccine could offer a more adaptable approach, potentially allowing for quicker updates to address emerging strains. Even though, the effectiveness of mCombriax against future variants will require ongoing monitoring and potential adjustments to the vaccine’s composition.
The potential benefits of mCombriax extend beyond individual protection. By reducing the incidence of both influenza and COVID-19, the vaccine could alleviate pressure on healthcare systems, decrease hospitalizations, and minimize disruptions to daily life. The economic impact of reduced illness and increased productivity could also be substantial.
While the FDA’s decision to decline review of mCombriax in the United States is a setback for Moderna in that market, the EMA’s positive opinion underscores the potential of this innovative vaccine. The reasons for the FDA’s decision were not immediately detailed, but the company may pursue further discussions with the agency regarding potential pathways for approval.
The EMA’s decision is based on a rigorous scientific review of the clinical trial data. The agency assessed the vaccine’s safety, efficacy, and quality, concluding that the benefits outweigh the risks for individuals aged 50 and older. Detailed information about the clinical trial results will be made available to healthcare professionals and the public following the European Commission’s final decision.
Individuals interested in learning more about mCombriax and the approval process can visit the European Medicines Agency website: https://www.ema.europa.eu/en/medicines/human/EPAR/mcombriax. Further updates will be provided as the European Commission reviews the CHMP’s recommendation and individual EU member states implement their national approval processes.
The next step in the process is the European Commission’s review of the CHMP’s positive opinion. A decision from the Commission is expected in the coming weeks. Following Commission approval, national regulatory authorities within the EU will determine the specific rollout plans for mCombriax in their respective countries.
This is a developing story. Share your thoughts in the comments below, and please share this article with your network.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
